CytoMed Therapeutics Limited (GDTC)

Every figure this model derived for GDTC, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2025-12-31.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 496,034 PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities 2025-12-31
cash 1,629,589 CashAndCashEquivalents 2025-12-31
current assets 2,848,569 CurrentAssets 2025-12-31
current liabilities 551,496 CurrentLiabilities 2025-12-31
equity 5,089,390 EquityAttributableToOwnersOfParent 2025-12-31
interest expense 16,258 InterestExpense 2025-12-31
ocf -2,875,389 CashFlowsFromUsedInOperatingActivities 2025-12-31
revenue 252,265 Revenue 2025-12-31
sbc 539,855 AdjustmentsForSharebasedPayments 2025-12-31

The ratios

The figures themselves rather than their scores — what somebody looking up GDTC on one particular measure came for.

RatioValue
current ratio5.17
current ratio reported5.17
dilution pct0.93
fcf margin-1336.46
owner earnings margin-1550.46
revenue growth395.88
revenue growth per share391.31
sbc pct revenue214.0

What to be careful about

What this model itself distrusts about GDTC's figures. Written by the derivation as it ran, not added afterwards.